NED Biosystems, Inc.

📍 Cambridge, United States🗓 Founded 2008👥 8 employees💰 Last funded Sep 2022

Founded to allow patients to achieve and sustain No Evidence of Disease NED Biosystems™ was founded to develop safe, efficacious, and comprehensive “systems” treatments for complex disease, beginning with the development of the patented NED-170 for treatment of cancer. A systems-based approach to treat disease comprehensively targets the behavior of the entire biological system instead of a single component. We begin with a focus on patients and their families. NED seeks to dramatically improve patients’ outcomes with treatments that lack the toxicity and side effects of today’s treatments, allowing patients a high quality of life. NED-170 takes a systems approach that combines repurposed, oral agents well-documented in humans to affect critical cancer disease-driver processes at doses that lack customary toxicity and side effects. 50%-80% of all cancer patients have no genetically sequenced “matched” therapy options. NED-170 is designed to initially treat these patients. When the pandemic hit NED deployed its systems methodology to develop NED-260 to be a universal antiviral treatment for existing infectious diseases and those not yet known. NED-260 is designed to protect multiple pathways within patients’ cells from attack by a broad range of viruses. NED-260’s treatment goal is to act early in the infection process to minimize, or eliminate, the advancement to severe disease, ideally allowing many patients to recover at home.

Total investors

Early stage

Mid stage

Late stage

2008

Founded